Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ALDH inhibitor NYH817G and mitochondrial complex 1 inhibitor NYH100P

An orally bioavailable combination agent composed of the aldehyde dehydrogenase (ALDH) inhibitor NYH817G and the mitochondrial complex 1 (NADH-ubiquinone oxidoreductase) inhibitor NYH100P, with potential antineoplastic activity. Upon oral administration of ALDH inhibitor NYH817G and mitochondrial complex 1 inhibitor NYH100P, NYH817G targets and binds to ALDH, and prevents the formation of NADH. It also inhibits lactate dehydrogenase A (LDH-A), thereby preventing lactate formation from pyruvate. NYH100P targets and binds to MC1. This all blocks the cancer cell energy production pathway, deprives tumor cells of nutrients, and energy, and inhibits nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:NYH817G and NYH100P
NYH817G plus NYH100P
NYH817G/NYH100P
Foreign brand name:Starvanip
Code name:NYH817100
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search